SCHEMBL1823356

SCHEMBL1823356

CC(=O)OC(C)(CNC(=O)OC(C)(C)C)c1cccc(OS(=O)(=O)c2ccc(C)cc2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR17 Q13304 2/20 0.40
MAPT P10636 2/20 0.39
GAA P10253 1/20 0.39
G6PD P11413 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
EGFR P00533 1/20 0.39
P2RX7 Q99572 2/20 0.39
F2 P00734 2/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
CA1 P00915 4/20 0.37
CA2 P00918 4/20 0.37
CA12 O43570 3/20 0.37
CA9 Q16790 3/20 0.37
ALDH1A1 P00352 3/20 0.37
ENPP2 Q13822 1/20 0.36
LMNA P02545 1/20 0.36
HPGD P15428 1/20 0.36
ACACB O00763 1/20 0.36
RECQL P46063 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1827247 0.92 CA1 (0.40) GPR17MAPTEGFRP2RX7F2
SCHEMBL1825189 0.91 GPR17 (0.41) GPR17MAPTGAAG6PDNPSR1
SCHEMBL1826927 0.88 EGFR (0.47) MAPTEGFRP2RX7MEN1KMT2A
SCHEMBL1826091 0.87 GPR17 (0.42) GPR17MAPTGAAG6PDNPSR1
SCHEMBL1826259 0.86 P2RX7 (0.46) GPR17MAPTGAAG6PDNPSR1
SCHEMBL1826489 0.86 CA1 (0.38) CA1CA2CA12CA9ALDH1A1
SCHEMBL1823064 0.83 CA1 (0.40) GPR17EGFRP2RX7F2CA1
SCHEMBL3571453 0.81 EGFR (0.46) MAPTEGFRP2RX7MEN1KMT2A
SCHEMBL1823079 0.80 P2RX7 (0.40) EGFRP2RX7CA1CA2CA12
SCHEMBL1825034 0.79 EGFR (0.48) MAPTEGFRP2RX7MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2161254-B1 Intermediate for preparing a biaryl compound SUMITOMO CHEMICAL CO (JP) 2014-08-13 EP disclosed
EP-1481967-B1 PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS SUMITOMO CHEMICAL CO (JP) 2011-05-04 EP disclosed
US-7714157-B2 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-05-11 US disclosed
EP-2161254-A1 Intermediate for preparing a biaryl compound Sumitomo Chemical Company, Limited (JP) 2010-03-10 EP disclosed
US-20070270603-A1 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED 2007-11-22 US disclosed
US-7271280-B2 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-09-18 US disclosed
EP-1481967-A1 PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS Sumitomo Chemical Company, Limited (JP) 2004-12-01 EP disclosed
US-20040158093-A1 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040158093-A1 Process for preparing a biaryl compound CYP1B1, REL, CYP2F1 GPR17 4205/4885MAPT 4712/4885GAA 2170/4885
US-20070270603-A1 Process for preparing a biaryl compound CYP4A11, CYP4B1, CYP51A1 GPR17 4459/4885MAPT 2237/4885GAA 98/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.